Table SI. Patient and cyclosporine A treatment characteristics

Patient characteristics at baseline (*n* = 88)	Children (*n* = 12)	Adults (*n* = 76)	Total (*n* = 88)
Age, years, mean (SD)	13.3 (4.2)	32.2 (11.2)	29.4 (12.3)
Sex, female, *n* (%)	2 (16.7)	20 (26.3)	22 (25.0)
Personal history of atopy, *n* (%)	7 (58.3)	65 (85.5)	72 (81.9)
Asthma	4 (33.3)	52 (68.4)	56 (63.7)
Rhinitis	4 (33.3)	52 (68.4)	56 (63.7)
Food allergy	3 (25)	11 (14.5)	14 (15.9)
Conjunctivitis	1 (8.3)	13 (17.1)	14 (15.9)
Age of onset of AD, *n* (%)			
0–9 years	12 (100)	57 (75)	69 (78.4)
9–18 years	0 (0)	5 (6.6)	5 (5.7)
>18 years	0 (0)	11 (4.5)	11 (12.5)
Previous treatments, *n* (%)			
Topical corticosteroid	12 (100)	76 (100)	88 (100)
Tacrolimus	6 (50)	41 (53.9)	47 (53.4)
Phototherapy	2 (16.7)	32 (42.1)	34 (38.6)
Hospitalization	8 (66.7)	45 (59.2)	53 (60.2)
AD severity, *n* (%)			
SCORAD < 20	0 (0)	1 (1.3)	1 (1.1)
SCORAD 20–40	1 (8.3)	11 (14.5)	12 (13.6)
SCORAD > 40	11 (91.7)	64 (84.2)	75 (85.2)
SCORAD mean (SD)	56.1 (14.7)	54.7 (15.4)	54.9 (15.2)
Duration of treatment, months: median (range)	4 (2.2–23.8)	9.3 (1–49.5)	8.23 (1–49.5)
Starting dose, mg/kg/day, mean (SD)	3.6 (0.6)	3.6 (0.6)	3.6 (0.6)
Starting dose > 3.5–5 mg/kg/day, *n* (%)	7 (58.3)	44 (57.9)	51 (58.0)
Staring dose ≤ 3.5 mg/kg/day, *n* (%)	5 (41.7)	32 (42.1)	37 (42.0)
Maximum dosage during treatment, mg/kg/day, mean (SD)	3.7 (0.5)	3.9 (0.6)	3.8 (0.63)
Adverse events, *n* (%)	4 (33.3)	46 (60.5)	50 (56.8)
Gastrointestinal symptoms	3 (25)	10 (13.2)	13 (14.8)
Neurological symptoms	0 (0)	13 (17.1)	13 (14.8)
Paraesthesia, dysaesthesia	0 (0)	9 (11.9)	9 (10.2)
Headache	0 (0)	2 (2.6)	2 (2.3)
Tremor	0 (0)	1 (1.3)	1 (1.1)
Hypertension	0 (0)	10 (13.2)	10 (11.4)
Serum creatinine increase[a]	0 (0)	10 (13.2)	10 (11.4)
Tiredness	0 (0)	6 (7.9)	6 (6.8)
Infection	2 (16.7)	2 (2.6)	4 (4.5)
Anorexia	1 (8.3)	1 (1.3)	2 (2.3)
Weight loss	1 (8.3)	1 (1.3)	2 (2.3)
Ionic disorder	0 (0)	2 (2.6)	2 (2.3)
Gingival hyperplasia	0 (0)	2 (2.6)	2 (2.3)
Hypertrichosis	0 (0)	1 (1.3)	1 (1.1)
Skin cancer	0 (0)	1 (1.3)	1 (1.1)
Adverse events by CTCAE grade, *n* (%)			
Grade 1	5 (33.3)	43 (56.6)	47 (53.4)
Grade 2	0 (0)	14 (18.4)	14 (15.9)
Grade 3 (Serious adverse events)	2 (16.7)	4 (5.3)	6 (6.8)

[a]Grade 1 (9), Grade 2 (1).
AD: atopic dermatitis; SD: standard deviation; CTCAE: Common Terminology Criteria for Adverse Events; SCORAD: SCORing Atopic Dermatitis.